abrdn Life Sciences Investors (HQL) Announces Results of Annual Meeting of Shareholders

Rhea-AI Summary

abrdn Life Sciences Investors (HQL) announced the results of its Annual Meeting of Shareholders held on June 25, 2024. Shareholders approved the election of two Class B Trustees to the Board: Stephen Bird with 84.4% votes for and Jeffrey Bailey with 81.9% votes for. A shareholder proposal regarding annual terms of trustees was opposed, with 55.1% votes against it. As of the April 1, 2024 record date, HQL had 27,350,517 outstanding shares, with 87.84% of them being voted. The meeting achieved a quorum. The fund's investment return and principal value fluctuate, and its shares may trade at a premium or discount to the NAV.

Positive

• Election of two Class B Trustees, Stephen Bird with 84.4% votes and Jeffrey Bailey with 81.9% votes.
• High shareholder participation with 87.84% of outstanding common stock voted.

Negative

• Shareholder proposal regarding annual terms of trustees was opposed by 55.1% of the votes.

PHILADELPHIA, PA / ACCESSWIRE / June 26, 2024 / abrdn Life Sciences Investors ("HQL") announced today the results of the Annual Meeting of Shareholders (the "Meeting"), held on June 25, 2024.

As of the record date, April 1, 2024, HQL had outstanding 27,350,517 shares of common stock. 87.84% of outstanding common stock were voted representing a quorum.

Shareholders approved the election of two Class B Trustees to the Board to serve until 2027 Annual Meeting by the following votes:

	Number of Votes Cast For	Percentage of Votes Cast For	Number of Votes Cast Against/Withheld	Percentage of Votes Cast Against / Withheld
Stephen Bird	20,269,963	84.4%	3,753,701	15.6%
Jeffrey Bailey	19,670,734	81.9%	4,352,930	18.1%

Shareholders opposed a shareholder proposal regarding annual terms of trustees by the following votes:

Number of Votes Cast For	Percentage of Votes Cast For	Number of Votes Cast Against/Withheld	Percentage of Votes Cast Against / Withheld	Number of Votes Abstained	Percentage of Votes Abstained
6,891,241	41.6%	9,133,348	55.1%	533,327	3.3%

In the United States, abrdn is the marketing name for the following affiliated, registered investment advisers: abrdn Inc., abrdn Investments Limited, abrdn Asia Limited, and abrdn ETFs Advisors LLC.

Closed-end funds are traded on the secondary market through one of the stock exchanges. A Fund's investment return and principal value will fluctuate so that an investor's shares may be worth more or less than the original cost. Shares of closed-end funds may trade above (a premium) or below (a discount) the net asset value (NAV) of the fund's portfolio. There is no assurance that a Fund will achieve its investment objective. Past performance does not guarantee future results.

www.abrdnhql.com

# # #

For More Information Contact:
abrdn U.S. Closed-End Funds
Investor Relations
800-522-5465
Investor.Relations@abrdn.com

SOURCE: abrdn U.S. Closed-End Funds

View the original press release on accesswire.com

FAQ

When was abrdn Life Sciences Investors' Annual Meeting of Shareholders held?

The Annual Meeting of Shareholders was held on June 25, 2024.

What percentage of shares were voted at HQL's Annual Meeting of Shareholders?

87.84% of outstanding common stock were voted at the meeting.

Who were elected as Class B Trustees for HQL?

Stephen Bird and Jeffrey Bailey were elected as Class B Trustees.

What was the result of the shareholder proposal regarding annual terms of trustees at HQL's meeting?

The shareholder proposal was opposed, with 55.1% of votes against it.

How many shares of common stock did HQL have outstanding as of April 1, 2024?

HQL had 27,350,517 shares of common stock outstanding as of April 1, 2024.